943320-61-4

Basic information

• Product Name: 3-Ethynylimidazo[1,2-b]pyridazine
• Synonyms: 3-Ethynylimidazo[1,2-b]pyridazine;IMidazo[1,2-b]pyridazine, 3-ethynyl-;3-Ethynylimidazolo[1,2-b]pyridazine
• CAS NO: 943320-61-4
• Molecular Formula: C8H5N3
• Molecular Weight: 143.1454
• Mol File: 943320-61-4.mol
• Article Data: 20

Chemical Properties

• Appearance: /
• Density: 1.15±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.71±0.30(Predicted)
• CAS DataBase Reference: 3-Ethynylimidazo[1,2-b]pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Ethynylimidazo[1,2-b]pyridazine(943320-61-4)
• EPA Substance Registry System: 3-Ethynylimidazo[1,2-b]pyridazine(943320-61-4)

Safety Data

• Hazardous Substances Data: 943320-61-4(Hazardous Substances Data)

Usage

Description

3-Ethynylimidazo[1,2-b]pyridazine is a heterocyclic organic compound with the molecular formula C8H5N3. It is characterized by a pyridazine ring fused to an imidazole ring, which classifies it within the imidazo[1,2-b]pyridazine family. This chemical compound is recognized for its potential biological activities, including anticancer and antiviral properties, and has been the subject of research for its ability to inhibit cancer cell growth and act as an anti-inflammatory agent. It is considered a promising candidate for the development of new pharmaceuticals, with ongoing studies to explore its therapeutic applications and potential uses.

Uses

Used in Pharmaceutical Industry:
3-Ethynylimidazo[1,2-b]pyridazine is used as a potential drug candidate for its anticancer properties, targeting the inhibition of cancer cell growth. It is being studied for its ability to impact various cancer types by interfering with essential biological processes within the cells, thereby offering a new avenue for cancer treatment.
3-Ethynylimidazo[1,2-b]pyridazine is also used as an antiviral agent, leveraging its potential to inhibit viral replication and activity, which could be beneficial in the development of treatments for viral infections.
Used in Research Applications:
In the field of scientific research, 3-Ethynylimidazo[1,2-b]pyridazine serves as a subject of study for understanding its mechanism of action, including how it interacts with biological systems and its potential as an anti-inflammatory agent. This research is crucial for identifying new therapeutic targets and developing more effective treatments for various diseases.
Further exploration of 3-Ethynylimidazo[1,2-b]pyridazine's applications is ongoing, with the aim of discovering additional uses across different industries where its unique properties can be harnessed for beneficial outcomes.

Upstream product

• 766-55-2 imidazo[1.2-b]pyridazine 
• 74-86-2 acetylene 
• 18087-73-5 3-bromo-imidazo[1,2-b]pyridazine 
• 1066-54-2 trimethylsilylacetylene 
• 943320-60-3 2-imidazo[1,2-b]pyridazin-3-ylethynyl(trimethyl)silane 

Relevant articles and documents

N-(3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYLPHENYL)-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING KINASE-RELATED DISEASES

The N-(3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylphenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide derivative exhibits excellent inhibitory activity against at least one kinase selected from the group consisting of ABL1, ABL2, AURKB, BRK, CDK11

ABELSON NON-TYROSINE KINASE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

The present disclosure relates to compounds for the use of treating neurodegenerative diseases and, in particular, to compounds targeting the Abelson non-tyrosine kinase (c-Abl) protein for such treatment. The neurological disorders and conditions include Parkinson's disease, Alzheimer's disease and the like. It also relates to pharmaceutical compositions and methods of treatment of such neurological disorders involving the c-Abl protein kinase.

Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease

Parkinson's disease (PD) is a debilitating and common neurodegenerative disease. New insights implicating c-Abl activation as a driving force in PD have opened a new drug development avenue for PD treatment beyond the symptomatic relief by L-DOPA. BCR-Abl inhibitors, which include nilotinib and ponatinib, have been found to inhibit this process, and nilotinib has shown improvement in outcomes in a 12-patient, nonrandomized trial. However, nilotinib is a potent inhibitor of hERG, a cardiac K+ channel whose inhibition increases risk of sudden death. We used our machine learning approach to predict novel molecules that would inhibit c-Abl while also having minimal liability against hERG. Of our six novel compounds tested, we identified two that had c-Abl potencies comparable to nilotinib, but with significantly improved profiles regarding the hERG channel. Our best compound exhibited a hERG IC50 of 12.1 μM (compared to nilotinib with an IC50 of 0.45 μM and ponatinib with IC50 of 0.767 μM). This work is a step forward for a machine learning enabled, multiparameter optimization of a chemical space and represents a significant advance in the development of novel Parkinson's therapies.